Patents by Inventor Michael G. Rosenblum
Michael G. Rosenblum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230203467Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: November 3, 2022Publication date: June 29, 2023Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 11535838Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: June 15, 2020Date of Patent: December 27, 2022Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Patent number: 10920211Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: September 19, 2019Date of Patent: February 16, 2021Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20200308565Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: June 15, 2020Publication date: October 1, 2020Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 10738295Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: April 30, 2019Date of Patent: August 11, 2020Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20200010821Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: September 19, 2019Publication date: January 9, 2020Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Publication number: 20190256837Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: April 30, 2019Publication date: August 22, 2019Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 10323239Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: March 9, 2018Date of Patent: June 18, 2019Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20180201918Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: March 9, 2018Publication date: July 19, 2018Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 9951325Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: July 2, 2014Date of Patent: April 24, 2018Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Patent number: 9499807Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: July 2, 2014Date of Patent: November 22, 2016Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Patent number: 9388397Abstract: Recombinant gelonin polypeptides with decreased antigenicity are provided. Cell-targeted constructs comprising said recombinant gelonin polypeptides are also provided. Such constructs can be used in methods for targeted cell killing, such as for treatment of cell proliferative diseases (e.g., cancer).Type: GrantFiled: February 14, 2014Date of Patent: July 12, 2016Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Lawrence Cheung
-
Publication number: 20150368628Abstract: Recombinant gelonin polypeptides with decreased antigenicity are provided. Cell-targeted constructs comprising said recombinant gelonin polypeptides are also provided. Such constructs can be used in methods for targeted cell killing, such as for treatment of cell proliferative diseases (e.g., cancer).Type: ApplicationFiled: February 14, 2014Publication date: December 24, 2015Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Lawrence CHEUNG
-
Patent number: 9096840Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: October 4, 2013Date of Patent: August 4, 2015Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20150010556Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Publication number: 20140314760Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Publication number: 20140140976Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: October 4, 2013Publication date: May 22, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 8530225Abstract: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.Type: GrantFiled: October 25, 2011Date of Patent: September 10, 2013Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Yuying Liu
-
Publication number: 20120252097Abstract: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.Type: ApplicationFiled: October 25, 2011Publication date: October 4, 2012Inventors: Michael G. Rosenblum, Yuying Liu
-
Patent number: 8138311Abstract: The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.Type: GrantFiled: April 26, 2011Date of Patent: March 20, 2012Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Lawrence Cheung